SCHEMBL2866098

SCHEMBL2866098

CCCCCOc1ccc(NC(=S)NC(=O)c2cccnc2C(=O)N2CCOCC2)cc1C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 3/20 0.43
ALDH1A1 P00352 4/20 0.41
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MET P08581 1/20 0.40
KDR P35968 1/20 0.40
HTT P42858 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
RAF1 P04049 1/20 0.38
ARAF P10398 1/20 0.38
BRAF P15056 1/20 0.38
PTPN1 P18031 1/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 1/20 0.38
MAPK14 Q16539 1/20 0.38
KCNH2 Q12809 1/20 0.38
TP53 P04637 1/20 0.37
THRB P10828 1/20 0.37
CSF1R P07333 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2867506 0.87 S1PR1 (0.44) S1PR1ALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL2863411 0.86 HTR2A (0.50) S1PR1RAF1ARAFBRAFHTR2A
SCHEMBL2868306 0.84 NPC1 (0.49) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL2864670 0.84 NPC1 (0.49) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL2865604 0.84 S1PR1 (0.49) S1PR1ALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL3146275 0.83 S1PR1 (0.43) S1PR1ALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL2863994 0.83 S1PR1 (0.50) S1PR1ALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL2868160 0.83 S1PR1 (0.50) S1PR1ALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL14096277 0.82 MEN1 (0.50) S1PR1ALDH1A1MAPTHTTMEN1
SCHEMBL2866090 0.82 MET (0.47) S1PR1ALDH1A1MAPTMETKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101087755-A Substituted arylacylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS INC (US) 2007-12-12 CN claimed
EP-1747196-A2 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION Achillion Pharmaceuticals, Inc. (US) 2007-01-31 EP claimed
WO-2006083271-A2 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2006-08-10 WO claimed
US-20060025416-A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-02-02 US claimed
US-7767706-B2 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2010-08-03 US disclosed
US-20090023730-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS (US) 2009-01-22 US disclosed
US-20060025416-A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025416-A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication PIGS, NAT1, AADAC S1PR1 1409/4885ALDH1A1 176/4885MAPT 3157/4885
US-20090023730-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION PIGS, NAT1, AADAC S1PR1 1409/4885ALDH1A1 176/4885MAPT 3157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.